| 分析师： [Tabl | 糜韩杰 | 分析师： | 左琴琴 | 分析师： | 董建芳 | | --- | --- | --- | --- | --- | --- | | e_Author] | SAC 执证号：S0260516020001 | | SAC 执证号：S0260521050001 | | SAC 执证号：S0260525060002 | | | SFC CE.no: BPH764 | | SFC CE.no: BSE791 | | | | | 021-38003650 | | 021-38003540 | | | | | mihanjie@gf.com.cn | | zuoqinqin@gf.com.cn | | dongjianfang@gf.com.cn | | | 请注意，董建芳并非香港证券及期货事务监察委员会的注册持牌人，不可在香港从事受监管活动。 | | | | | [Table_Summary] 核心观点： 相关研究 [Table_Report ： ] [Table_Page] 行业专题研究|纺织服饰 2026 年 3 月 20 日 证券研究报告 [Table_Title] 纺织服 ...

Investment Rating - Industry rating: Recommended [5] Core Insights - The report highlights significant growth in the textile and apparel industry, with major companies like On Running and Adidas reporting record sales and profits for 2025. On Running's net sales reached 3.014 billion Swiss Francs, a 30% increase year-on-year, while Adidas reported global revenue of 24.8 billion Euros, a 13% increase [2][3]. Summary by Sections Company Performance - On Running's net sales for 2025 reached 3.014 billion Swiss Francs, a 30% increase year-on-year, with a net profit of 203 million Swiss Francs, down 15.9%. The gross margin improved to 62.8% [2]. - Adidas achieved a record global revenue of 24.8 billion Euros, up 13% year-on-year, with operating profit increasing by 54% to 2.06 billion Euros and net profit rising over 70% to 1.34 billion Euros [3]. Regional Performance - On Running's sales in the Asia-Pacific region surged by 96.4% to 511 million Swiss Francs, while EMEA sales increased by 32% to 763 million Swiss Francs, and Americas sales rose by 17.6% to 1.740 billion Swiss Francs [2]. - Adidas reported a 13% increase in Greater China sales to 3.62 billion Euros, marking eleven consecutive quarters of growth, with a 15% increase in Q4 [3]. Product Category Performance - On Running's apparel sales grew by 68.2% to 170 million Swiss Francs, accessories by 124.1% to 37 million Swiss Francs, and footwear by 27.5% to 2.804 billion Swiss Francs [2]. - Adidas saw footwear revenue increase by 12% to 1.423 billion Euros, with running business revenue growing over 30% [3]. Financial Health - On Running reported a cash reserve exceeding 1 billion Swiss Francs and an operating cash flow of 359.5 million Swiss Francs [2]. - Adidas improved its operating expense ratio from 34.2% to 31.4%, with inventory rising by 70% as part of preparations for 2026 growth [3]. Future Guidance - On Running expects net sales to grow at least 23% in 2026, with a gross margin of no less than 63% and an adjusted EBITDA margin of 18.5%-19% [2]. - Adidas anticipates near double-digit revenue growth in 2026, with a focus on key markets and product categories, projecting an operating profit of around 2.3 billion Euros [3]. Investment Recommendations - The report recommends several companies based on current market conditions, including Baolong Oriental, New Australia, and Fuchun Dyeing & Weaving in the manufacturing sector, and Jin Hong Group, Ge Li Si, and Luo Lai Life in the brand sector [4][17].

Investment Rating - The industry rating is "Recommended" [6] Core Insights - Amer Sports reported Q4 and full-year results for 2025, exceeding market expectations with revenue and net profit growth of 27% and 489% respectively, with Greater China revenue increasing by 43.4% [3][15] - Jiangnan Buyi's FY2026H1 revenue, net profit, and operating cash flow were 3.376 billion, 676 million, and 996 million CNY, reflecting year-on-year growth of 7.0%, 11.9%, and 21.1% respectively [4][16] - The report highlights a strong expectation for upstream price increases in manufacturing, particularly for wool and cotton, with recommendations for specific companies benefiting from these trends [5][17] Summary by Sections Company Performance - Amer Sports' brand performance showed significant growth, with Arc'teryx, Salomon, and Wilson revenues increasing by 30%, 31%, and 13% respectively [3][15] - Jiangnan Buyi declared an interim dividend of 0.52 HKD per share, yielding a 5.18% dividend rate [4][16] Market Trends - The report notes a strong expectation for price increases in raw materials, including wool and cotton, with recommendations for companies like Baolong Oriental and New Australia [5][17] - The easing of tariffs is expected to positively impact the industry, with a potential reduction of 5%-10% in tariffs on Chinese goods exported to the U.S. [4][16] Online Sales Data - Sales data from Taobao and Tmall for January 2026 showed a year-on-year increase in sportswear sales by 15.81%, indicating a recovery in consumer demand [5][17] - The outdoor category saw significant growth, with sales for outdoor climbing and camping gear increasing by 25.63% [5][17] Raw Material Prices - As of February 27, 2026, the Chinese cotton price index rose to 16,731 CNY/ton, reflecting a 3.88% increase [8][32] - Wool prices have increased by 4.13% year-to-date, with the Australian wool market index at 1,716 AUD/kg [8][39] Export Data - In 2025, textile and apparel exports decreased by 2.26% year-on-year, with textile exports growing by 0.5% and apparel exports declining by 5% [51][52] - Vietnam's footwear exports showed a positive trend, with a year-on-year increase of 7.79% in January 2026 [60][61]

Group 1 - The core viewpoint of the article is that the company, Weijian Medical, is collaborating with Wuhan Textile University to establish a talent training program aimed at enhancing its technical research and development capabilities for future growth [1] - This partnership is part of the company's initiative to support talent cultivation and strengthen its research and development foundation, which will contribute to long-term technological accumulation and innovation capacity [1] - The company plans to leverage the university-industry cooperation platform to continuously focus on the development of textile material technology, providing necessary talent support for its business development [1]

Group 1 - The article highlights the stock recommendations from various securities firms, with a total of 21 listed companies receiving recommendations on February 25 [2] - Supor received the highest number of recommendations, with three firms suggesting a buy, while companies like Yuheng Pharmaceutical and Bohai Leasing received one recommendation each [2] - The recommended target prices and potential price increases for the stocks include Supor at 60.45 with a potential increase of 34.84%, and Yuheng Pharmaceutical at 3.64 with a potential increase of 6.74% [2] Group 2 - On February 25, eight companies received initial coverage from securities firms, with Hongchuan Wisdom rated as "Buy" by Huayuan Securities [4] - Other companies receiving "Buy" ratings include Runben Co. by Dongguan Securities, Qianyan Bio by Changjiang Securities, and Zhongtian Technology by Zhongyou Securities [4][5] - The sectors represented in the initial coverage include logistics, personal care products, chemical pharmaceuticals, communication equipment, and photovoltaic equipment [5]

Group 1 - On February 25, 21 listed companies received broker recommendations, with Supor (002032) receiving the highest number of recommendations at 3 [2][3] - The latest ratings for Supor (002032) include a "Outperform" from China International Capital Corporation with a target price of 60.45 yuan, indicating a potential upside of 34.84% [2] - Other companies with notable recommendations include Silan Microelectronics (600460) with a "Buy" rating from Qunyi Securities (Hong Kong) and a target price of 45.00 yuan, representing a potential upside of 38.50% [2] Group 2 - Eight companies received initial coverage on February 25, with Hongchuan Wisdom (002930) rated "Buy" by Huayuan Securities in the logistics sector [4] - Runben Co., Ltd. (603193) was rated "Buy" by Dongguan Securities in the personal care products industry [4] - Other companies receiving initial ratings include Zhongtian Technology (600522) with a "Buy" rating from Zhongyou Securities in the communication equipment sector and Yongzhen Co., Ltd. (603381) rated "Increase Holding" by China Merchants Securities in the photovoltaic equipment sector [4]

Investment Rating - The report maintains an "Outperform" rating for the textile and apparel industry [1] Core Insights - As China enters a deeply aging society, the aging population presents both social challenges and significant market opportunities for the silver economy. Companies actively positioning themselves in this sector are expected to experience growth [2] - The silver economy is becoming a crucial growth engine in the consumer market, driven by increased health awareness and the expanding demand for healthcare and age-friendly products among the elderly population [2] Summary by Sections Sports Apparel - The consumption of sports shoes and apparel remains robust in Japan's aging society, with the mass sports industry experiencing growth despite economic downturns. This trend is mirrored in China, where the middle-aged and elderly population is increasingly participating in low-barrier sports like running, leading to a surge in demand for professional running shoes. The sports shoe and apparel market in China is projected to reach 437.7 billion RMB by 2025, with outdoor trail running shoes expected to grow over 150% [2][5][33] Steady Medical - Steady Medical is leveraging its dual-brand strategy with "Winner Steady Medical" and "Purcotton" to tap into the silver economy. The medical segment focuses on high-end wound dressings, with a projected compound annual growth rate (CAGR) of 40.5% from 2019 to 2024, driven by the growing demand for chronic disease care among the elderly. The consumer segment is expanding its adult incontinence product line, with a CAGR of 18.6% from 2019 to 2024, emphasizing safety and comfort [2][58][67] Investment Recommendations - The report suggests focusing on opportunities in the sports industry and age-friendly products within the silver economy. It highlights the potential of domestic sports brands catering to a wide demographic, including both young and elderly consumers. Key recommended stocks include Li Ning, Anta Sports, Xtep International, and 361 Degrees, along with Steady Medical for its strong product offerings in high-quality cotton consumer goods and advanced medical dressings [2][4][57]

Investment Rating - The report maintains an "Outperform" rating for the textile and apparel industry [1] Core Insights - As China enters a deeply aging society, the aging population presents both social challenges and significant consumption market opportunities for the silver economy. Companies actively positioning themselves in this sector are expected to experience new growth opportunities [2] - The silver economy is becoming a crucial growth engine in the consumer market, driven by increased health awareness and the expanding demand for healthcare and age-friendly products among the elderly population [2] Summary by Sections Sports Apparel - The aging population in Japan has led to stable consumption of sports shoes and apparel, with the public's health awareness driving growth in the sports industry. Similar trends are observed in China, where the participation rate in low-barrier sports like running is significantly increasing among the elderly [2][5] - The sports apparel market in China is projected to reach 437.7 billion RMB by 2025, with outdoor trail running shoes expected to grow over 150% [2][47] Steady Medical - Steady Medical is leveraging its dual-brand strategy with "Winner Steady Medical" and "Purcotton" to tap into the silver economy. The medical segment focuses on high-end wound dressings, with a compound annual growth rate (CAGR) of 40.5% expected from 2019 to 2024, driven by the growing demand for chronic disease care among the elderly [2][58] - The adult incontinence brand "Light Skin Theory" is gaining traction, with a CAGR of 18.6% expected for the adult apparel business from 2019 to 2024, emphasizing safety and comfort [2][58] Investment Recommendations - The report suggests focusing on opportunities in the sports industry and age-friendly products within the silver economy. It highlights strong domestic sports brands like Li Ning, Anta Sports, and Xtep International, which are well-positioned to meet the diverse needs of consumers across all age groups [2][5][57]

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Steady Medical (300888) as of February 25, 2026, with a closing price of 35.49 yuan, reflecting a 1.31% increase [1] - The company reported a main revenue of 7.897 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 30.1%, and a net profit attributable to shareholders of 732 million yuan, up 32.36% year-on-year [2] - In Q3 2025, the company achieved a single-quarter main revenue of 2.601 billion yuan, a 27.71% increase year-on-year, and a net profit of 240 million yuan, which is a 42.11% increase year-on-year [2] Group 2 - The company has a debt ratio of 33.87% and reported investment income of 33.23 million yuan, with financial expenses of -2.036 million yuan, and a gross profit margin of 48.32% [2] - Over the past 90 days, five institutions have provided ratings for the stock, with four buy ratings and one hold rating, and the average target price set by institutions is 5.207 billion yuan [2]

Investment Rating - The report maintains a "Buy-A" investment rating for the company, with a target price of 46.75 CNY based on a 19x PE for 2026 [3][5]. Core Insights - The company's growth strategy for 2026 is clearly defined, focusing on a dual-driven approach of "medical + consumer" sectors, aiming to enhance efficiency and expand market presence [1]. - The medical segment's growth will be driven by both internal structural optimization and external acquisitions, particularly highlighting the acquisition of the US-based GRI company, which is expected to significantly boost revenue starting in 2025 [1]. - The consumer segment's growth is primarily fueled by brand strength and category expansion, with a focus on high-repurchase-rate products such as maternal and infant care items [1][2]. Summary by Sections Company Overview - The company is positioned to leverage its dual-driven strategy to enhance profitability and market share in both medical and consumer sectors [1]. Financial Performance - In Q3 2025, the company reported a revenue of 2.6 billion CNY, a year-on-year increase of 27.7%, and a net profit of 240 million CNY, up 42.1% year-on-year [2]. - The medical segment benefited from overseas market expansion, with foreign sales channels increasing by 81.7% year-on-year [2]. Future Projections - Revenue projections for 2025-2027 are estimated at 10.368 billion CNY, 12.156 billion CNY, and 14.274 billion CNY, representing growth rates of 15.49%, 17.24%, and 17.42% respectively [3][6]. - Net profit forecasts for the same period are 1.071 billion CNY, 1.433 billion CNY, and 1.871 billion CNY, with growth rates of 54.01%, 33.78%, and 30.56% respectively [3][6].